Market Cap 587.97M
Revenue (ttm) 2.37M
Net Income (ttm) -62.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,650.21%
Debt to Equity Ratio 0.00
Volume 3,039,100
Avg Vol 429,584
Day's Range N/A - N/A
Shares Out 53.79M
Stochastic %K 62%
Beta N/A
Analysts Strong Sell
Price Target $55.00

Company Profile

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 781 208 2466
Address:
890 Winter Street, Suite 200, Waltham, United States
Wyckly670
Wyckly670 Jun. 27 at 5:10 PM
$MODV vs $GME long term double bottom setup. $ZBIO & $UPB potential trend reversal with upcoming FDA catalysts. $CDTX ...
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 16 at 1:50 AM
Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency $UPB $AMGN https://stocktwits.com/news/equity/markets/upstream-bio-stock-gets-a-boost-as-new-lung-inflammation-drug-shows-higher-potency/chlnBRHRRbq
0 · Reply
DonCorleone77
DonCorleone77 Jun. 16 at 12:47 AM
$UPB Upstream Bio announces presentation of data on verekitug's TSLP receptor Upstream Bio announced the presentation of translational pharmacology modeling data supporting verekitug's Thymic Stromal Lymphopoietin, TSLP, receptor targeting as a mechanism for greater potency when compared to treatments targeting the TSLP ligand. Data were presented at the European Academy of Allergy & Clinical Immunology, EAACI, Congress taking place June 13-16, 2025, in Glasgow, United Kingdom. Data presented used an in silico system pharmacology modeling approach to provide a mechanism-based understanding for the observed potency of verekitug and are summarized as follows: Semi-mechanistic pharmacokinetic/pharmacodynamic models were built using the same biological and drug-specific parameters for verekitug and tezepelumab and populated with observed clinical data for verekitug and published clinical data for tezepelumab. Across a range of doses, PK/PD model simulations predict complete and sustained inhibition of the TSLP/TSLPR complex with verekitug compared to tezepelumab. Dose-response model simulations predict that potent inhibition of the TSLP/TSLPR complex would result in a greater reduction in fractional exhaled nitric oxide, a biomarker of lung inflammation. Modeling data indicated that the greater predicted reduction of FeNO observed with verekitug, compared with published data for tezepelumab, is potentially driven by lower expression levels of the TSLP receptor over time versus the ligand, as well as slower protein turnover time for the TSLP receptor versus the ligand.
1 · Reply
G101SPM
G101SPM Jun. 11 at 6:28 PM
#SHOWTIME European Academy of Allergy and Clinical Immunology Congress (June 12-15) Scheduled to appear: $JSPR, $PHVS, $UPB
0 · Reply
boohoooomillenials
boohoooomillenials Jun. 11 at 1:27 PM
$UPB taking some here. 6 months play
0 · Reply
Klinsmann
Klinsmann Jun. 3 at 12:41 AM
$UPB 😎
0 · Reply
BioTechHealthX
BioTechHealthX May. 30 at 3:20 PM
$UPB's approach to blocking upstream inflammation with verekitug sets it apart in the battle against severe asthma and chronic rhinosinusitis. https://biotechhealthx.com/biotech-news/upstream-bio-upb-is-poised-to-disrupt-the-respiratory-disease-market/
0 · Reply
consumedbylife
consumedbylife May. 28 at 12:48 AM
$UPB 🧐
0 · Reply
Klinsmann
Klinsmann May. 27 at 5:29 PM
$UPB this is also a longer term investment imo
0 · Reply
DonCorleone77
DonCorleone77 Mar. 12 at 11:34 AM
$UPB Upstream Bio reports Q4 revenue $613K, consensus $384.75k "We closed 2024 and started 2025 with strong continued momentum, marked by the successful completion of enrollment in our Phase 2 clinical trial of verekitug in patients with CRSwNP in January 2025. We expect to report top-line data from this trial in the second half of 2025, enabling regulatory discussions and preparations for a Phase 3 program in CRSwNP," said Rand Sutherland, MD, Chief Executive Officer of Upstream.
0 · Reply
Latest News on UPB
Upstream Bio Appoints Stacy Price as Chief Technology Officer

May 20, 2025, 7:00 AM EDT - 5 weeks ago

Upstream Bio Appoints Stacy Price as Chief Technology Officer


3 Dividend Giants To Buy As Tariffs Hit Stocks

Mar 28, 2025, 3:56 PM EDT - 3 months ago

3 Dividend Giants To Buy As Tariffs Hit Stocks

PEP PG


Upstream Bio to Present at Upcoming March Investor Conferences

Feb 25, 2025, 8:00 AM EST - 4 months ago

Upstream Bio to Present at Upcoming March Investor Conferences


Upstream Bio Announces Addition to Russell 2000® Index

Dec 16, 2024, 8:00 AM EST - 6 months ago

Upstream Bio Announces Addition to Russell 2000® Index


Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Oct 11, 2024, 12:49 PM EDT - 9 months ago

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut


Upstream Bio raises $255 mln in US IPO

Oct 10, 2024, 7:42 PM EDT - 9 months ago

Upstream Bio raises $255 mln in US IPO


Upstream Bio IPO Registration Document (S-1)

Sep 18, 2024, 4:06 PM EDT - 10 months ago

Upstream Bio IPO Registration Document (S-1)


Wyckly670
Wyckly670 Jun. 27 at 5:10 PM
$MODV vs $GME long term double bottom setup. $ZBIO & $UPB potential trend reversal with upcoming FDA catalysts. $CDTX ...
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 16 at 1:50 AM
Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency $UPB $AMGN https://stocktwits.com/news/equity/markets/upstream-bio-stock-gets-a-boost-as-new-lung-inflammation-drug-shows-higher-potency/chlnBRHRRbq
0 · Reply
DonCorleone77
DonCorleone77 Jun. 16 at 12:47 AM
$UPB Upstream Bio announces presentation of data on verekitug's TSLP receptor Upstream Bio announced the presentation of translational pharmacology modeling data supporting verekitug's Thymic Stromal Lymphopoietin, TSLP, receptor targeting as a mechanism for greater potency when compared to treatments targeting the TSLP ligand. Data were presented at the European Academy of Allergy & Clinical Immunology, EAACI, Congress taking place June 13-16, 2025, in Glasgow, United Kingdom. Data presented used an in silico system pharmacology modeling approach to provide a mechanism-based understanding for the observed potency of verekitug and are summarized as follows: Semi-mechanistic pharmacokinetic/pharmacodynamic models were built using the same biological and drug-specific parameters for verekitug and tezepelumab and populated with observed clinical data for verekitug and published clinical data for tezepelumab. Across a range of doses, PK/PD model simulations predict complete and sustained inhibition of the TSLP/TSLPR complex with verekitug compared to tezepelumab. Dose-response model simulations predict that potent inhibition of the TSLP/TSLPR complex would result in a greater reduction in fractional exhaled nitric oxide, a biomarker of lung inflammation. Modeling data indicated that the greater predicted reduction of FeNO observed with verekitug, compared with published data for tezepelumab, is potentially driven by lower expression levels of the TSLP receptor over time versus the ligand, as well as slower protein turnover time for the TSLP receptor versus the ligand.
1 · Reply
G101SPM
G101SPM Jun. 11 at 6:28 PM
#SHOWTIME European Academy of Allergy and Clinical Immunology Congress (June 12-15) Scheduled to appear: $JSPR, $PHVS, $UPB
0 · Reply
boohoooomillenials
boohoooomillenials Jun. 11 at 1:27 PM
$UPB taking some here. 6 months play
0 · Reply
Klinsmann
Klinsmann Jun. 3 at 12:41 AM
$UPB 😎
0 · Reply
BioTechHealthX
BioTechHealthX May. 30 at 3:20 PM
$UPB's approach to blocking upstream inflammation with verekitug sets it apart in the battle against severe asthma and chronic rhinosinusitis. https://biotechhealthx.com/biotech-news/upstream-bio-upb-is-poised-to-disrupt-the-respiratory-disease-market/
0 · Reply
consumedbylife
consumedbylife May. 28 at 12:48 AM
$UPB 🧐
0 · Reply
Klinsmann
Klinsmann May. 27 at 5:29 PM
$UPB this is also a longer term investment imo
0 · Reply
DonCorleone77
DonCorleone77 Mar. 12 at 11:34 AM
$UPB Upstream Bio reports Q4 revenue $613K, consensus $384.75k "We closed 2024 and started 2025 with strong continued momentum, marked by the successful completion of enrollment in our Phase 2 clinical trial of verekitug in patients with CRSwNP in January 2025. We expect to report top-line data from this trial in the second half of 2025, enabling regulatory discussions and preparations for a Phase 3 program in CRSwNP," said Rand Sutherland, MD, Chief Executive Officer of Upstream.
0 · Reply
Greedy4money1
Greedy4money1 Feb. 28 at 8:19 PM
$UPB anyone work here with any feedback?
0 · Reply
Stonkey
Stonkey Feb. 11 at 2:14 PM
0 · Reply
DIORMAN
DIORMAN Feb. 10 at 10:32 PM
$UPB amazing......
0 · Reply
Stonkey
Stonkey Feb. 7 at 3:06 PM
0 · Reply
_www_larval_com_
_www_larval_com_ Feb. 4 at 8:53 PM
$CPIX 6%[57%] $UPB 4%[-11%] $XGN 4%[28%] $BDMD -3%[-10%] most notable movement into the final minutes of trading.
0 · Reply
Stonkey
Stonkey Feb. 3 at 5:13 PM
0 · Reply
Stonkey
Stonkey Jan. 31 at 8:30 PM
$UPB From bright green to blood red.....nothing more frustrating than trading bio stocks....
0 · Reply
Dxsiso01
Dxsiso01 Jan. 30 at 1:33 PM
$UPB $130 go up
0 · Reply
Dxsiso01
Dxsiso01 Jan. 30 at 12:36 PM
0 · Reply